GSK's Rotarix: A Theoretical Risk Isn't Enough To Keep It Off The Market

FDA's May 14 decision that GlaxoSmithKline's Rotarix and Merck's RotaTeq should be offered to the public, even after both vaccines were found to contain DNA from porcine circovirus, signals that the agency is valuing the benefits of the products over the theoretical risk